Bloomage Biotechnology Corp Ltd
SSE:688363
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (44.6), the stock would be worth ¥55.83 (29% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 34.5 | ¥43.24 |
0%
|
| 3-Year Average | 44.6 | ¥55.83 |
+29%
|
| 5-Year Average | 55.4 | ¥69.43 |
+61%
|
| Industry Average | 38.2 | ¥47.86 |
+11%
|
| Country Average | 18.3 | ¥22.87 |
-47%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Bloomage Biotechnology Corp Ltd
SSE:688363
|
20.7B CNY | 34.5 | 320.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 18.9 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 18.3 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 16 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 29.6 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 14.6 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 117.5 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 11.5 | 29.7 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Bloomage Biotechnology Corp Ltd
Glance View
Nestled in the bustling corridors of the biotechnology industry, Bloomage Biotechnology Corp Ltd. has carved a niche as a leading player specializing in the production and innovation of biopolymers, with a particular emphasis on hyaluronic acid. Since its inception, the company has embraced a scientific approach combined with a robust business strategy, propelling it to the forefront of biotechnological advancements. Its operations are underpinned by a relentless pursuit of research and development, utilizing cutting-edge fermentation technology to manufacture high-quality hyaluronic acid that serves various industries such as cosmetics, food, and pharmaceuticals. Bloomage’s revenue model is intricately linked to the diverse applications of hyaluronic acid. By supplying raw materials to cosmetic giants, the company significantly taps into the lucrative beauty industry, as this compound is highly valued for its skin hydration properties. Additionally, Bloomage is involved in the healthcare segment, where it provides key ingredients for medical products that enhance joint health and accelerate wound healing. Through strategic partnerships and a focus on high-margin products, Bloomage not only diversifies its revenue streams but also sustains its position in competitive markets. This deliberate orchestration of science and commerce ensures the company remains at the vanguard of both innovation and profitability.
